Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for MDxHealth (MDXH) over the last 6 years, with Q3 2025 value amounting to $111.4 million.

  • MDxHealth's Total Non-Current Liabilities rose 1740.12% to $111.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.4 million, marking a year-over-year increase of 1740.12%. This contributed to the annual value of $99.8 million for FY2024, which is 251.56% down from last year.
  • MDxHealth's Total Non-Current Liabilities amounted to $111.4 million in Q3 2025, which was up 1740.12% from $100.3 million recorded in Q2 2025.
  • In the past 5 years, MDxHealth's Total Non-Current Liabilities registered a high of $125.7 million during Q1 2025, and its lowest value of $11.7 million during Q4 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $97.0 million (2023), whereas its average is $90.5 million.
  • As far as peak fluctuations go, MDxHealth's Total Non-Current Liabilities plummeted by 958.72% in 2021, and later skyrocketed by 67967.81% in 2022.
  • MDxHealth's Total Non-Current Liabilities (Quarter) stood at $11.7 million in 2021, then skyrocketed by 679.68% to $91.5 million in 2022, then increased by 11.86% to $102.4 million in 2023, then dropped by 2.52% to $99.8 million in 2024, then rose by 11.58% to $111.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $111.4 million for Q3 2025, versus $100.3 million for Q2 2025 and $125.7 million for Q1 2025.